BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21622231)

  • 1. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity.
    Strobl B; Stoiber D; Sexl V; Mueller M
    Front Biosci (Landmark Ed); 2011 Jun; 16(9):3214-32. PubMed ID: 21622231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene.
    Leitner NR; Witalisz-Siepracka A; Strobl B; Müller M
    Cytokine; 2017 Jan; 89():209-218. PubMed ID: 26631911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.
    Li Z; Gakovic M; Ragimbeau J; Eloranta ML; Rönnblom L; Michel F; Pellegrini S
    J Immunol; 2013 Mar; 190(5):2335-44. PubMed ID: 23359498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.
    Fuchs S; Kaiser-Labusch P; Bank J; Ammann S; Kolb-Kokocinski A; Edelbusch C; Omran H; Ehl S
    Eur J Immunol; 2016 Nov; 46(11):2639-2649. PubMed ID: 27615517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TYK2 kinase activity is required for functional type I interferon responses in vivo.
    Prchal-Murphy M; Semper C; Lassnig C; Wallner B; Gausterer C; Teppner-Klymiuk I; Kobolak J; Müller S; Kolbe T; Karaghiosoff M; Dinnyés A; Rülicke T; Leitner NR; Strobl B; Müller M
    PLoS One; 2012; 7(6):e39141. PubMed ID: 22723949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
    Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
    Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative proteome analysis links tyrosine kinase 2 (Tyk2) to the regulation of cellular glucose and lipid metabolism in response to poly(I:C).
    Grunert T; Leitner NR; Marchetti-Deschmann M; Miller I; Wallner B; Radwan M; Vogl C; Kolbe T; Kratky D; Gemeiner M; Allmaier G; Müller M; Strobl B
    J Proteomics; 2011 Nov; 74(12):2866-80. PubMed ID: 21787891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.
    Sohn SJ; Barrett K; Van Abbema A; Chang C; Kohli PB; Kanda H; Smith J; Lai Y; Zhou A; Zhang B; Yang W; Williams K; Macleod C; Hurley CA; Kulagowski JJ; Lewin-Koh N; Dengler HS; Johnson AR; Ghilardi N; Zak M; Liang J; Blair WS; Magnuson S; Wu LC
    J Immunol; 2013 Sep; 191(5):2205-16. PubMed ID: 23894201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptome analysis reveals a major impact of JAK protein tyrosine kinase 2 (Tyk2) on the expression of interferon-responsive and metabolic genes.
    Vogl C; Flatt T; Fuhrmann B; Hofmann E; Wallner B; Stiefvater R; Kovarik P; Strobl B; Müller M
    BMC Genomics; 2010 Mar; 11():199. PubMed ID: 20338026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
    Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
    J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity.
    Minegishi Y; Saito M; Morio T; Watanabe K; Agematsu K; Tsuchiya S; Takada H; Hara T; Kawamura N; Ariga T; Kaneko H; Kondo N; Tsuge I; Yachie A; Sakiyama Y; Iwata T; Bessho F; Ohishi T; Joh K; Imai K; Kogawa K; Shinohara M; Fujieda M; Wakiguchi H; Pasic S; Abinun M; Ochs HD; Renner ED; Jansson A; Belohradsky BH; Metin A; Shimizu N; Mizutani S; Miyawaki T; Nonoyama S; Karasuyama H
    Immunity; 2006 Nov; 25(5):745-55. PubMed ID: 17088085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases.
    Muromoto R; Shimoda K; Oritani K; Matsuda T
    Biol Pharm Bull; 2021; 44(11):1585-1592. PubMed ID: 34719635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Atlantic salmon protein tyrosine kinase Tyk2: molecular cloning, modulation of expression and function.
    Sobhkhez M; Hansen T; Iliev DB; Skjesol A; Jørgensen JB
    Dev Comp Immunol; 2013 Dec; 41(4):553-63. PubMed ID: 23872231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyk2-signaling plays an important role in host defense against Escherichia coli through IL-23-induced IL-17 production by gammadelta T cells.
    Nakamura R; Shibata K; Yamada H; Shimoda K; Nakayama K; Yoshikai Y
    J Immunol; 2008 Aug; 181(3):2071-5. PubMed ID: 18641345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyk2 is a therapeutic target for psoriasis-like skin inflammation.
    Ishizaki M; Muromoto R; Akimoto T; Sekine Y; Kon S; Diwan M; Maeda H; Togi S; Shimoda K; Oritani K; Matsuda T
    Int Immunol; 2014 May; 26(5):257-67. PubMed ID: 24345760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
    Gerstenberger BS; Ambler C; Arnold EP; Banker ME; Brown MF; Clark JD; Dermenci A; Dowty ME; Fensome A; Fish S; Hayward MM; Hegen M; Hollingshead BD; Knafels JD; Lin DW; Lin TH; Owen DR; Saiah E; Sharma R; Vajdos FF; Xing L; Yang X; Yang X; Wright SW
    J Med Chem; 2020 Nov; 63(22):13561-13577. PubMed ID: 32787094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis.
    Hainzl E; Stockinger S; Rauch I; Heider S; Berry D; Lassnig C; Schwab C; Rosebrock F; Milinovich G; Schlederer M; Wagner M; Schleper C; Loy A; Urich T; Kenner L; Han X; Decker T; Strobl B; Müller M
    J Immunol; 2015 Nov; 195(10):5011-24. PubMed ID: 26432894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
    Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
    Front Immunol; 2022; 13():884399. PubMed ID: 35693820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
    Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
    Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides.
    Tran NV; Nguyen LTA; Lim KW; Phan AT
    Immunohorizons; 2021 Feb; 5(2):70-80. PubMed ID: 33542028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.